Aim: To evaluate the efficacy of pentoxifylline in the management of oral submucous fibrosis. Material and method: This randomized clinical trial was conducted in the Department of Oral Medicine and Radiology comprised of clinical case series of 60 patients distributed equally among study and control group. Pain and burning sensation were recorded using Visual Analogue Scale (VAS) which consists of a straight line with the end points defining extreme limits such as ‘no pain at all’ and ‘pain as bad as it could be.’ Mouth opening was measured by measuring the distance between the centre of incisal edges of maxillary central incisors and mandibular central incisor at maximum opened mouth using Vernier Calliper. 3 measurements were recorded consecutively and the average value was calculated and recorded in mm. The patients in either group were followed up after 1st month, 2nd month and 3rd month from commencement of the treatment of the respective therapies. Results: The difference among 1 month, 2 month, 3 month post–treatment pain assessment and mouth opening score among the study group and the control group is found to be statistically significant Conclusion: Pentoxifylline can be safer and better alternative treatment for oral submucous fibrosis. Larger sample size and longer treatment duration is necessary in this regard to validate results of the current study.